Edition:
United States

Mylan NV (MYL.O)

MYL.O on Nasdaq

37.07USD
17 Jan 2017
Change (% chg)

$0.34 (+0.93%)
Prev Close
$36.73
Open
$36.86
Day's High
$37.36
Day's Low
$36.45
Volume
4,542,867
Avg. Vol
6,309,119
52-wk High
$54.23
52-wk Low
$33.60

MYL.O

Chart for MYL.O

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment... (more)

Overall

Beta: 1.13
Market Cap(Mil.): $19,654.42
Shares Outstanding(Mil.): 535.11
Dividend: --
Yield (%): --

Financials

  MYL.O Industry Sector
P/E (TTM): 71.96 29.84 30.76
EPS (TTM): 0.51 -- --
ROI: 1.15 15.39 14.82
ROE: 2.38 16.58 16.24

CVS slashes price of Impax's EpiPen rival

Drugstore chain CVS Health Corp has cut the price of a generic version of Impax Laboratories Inc's emergency allergy injection, a device similar to Mylan NV's controversial EpiPen.

Jan 12 2017

CVS slashes price of Impax's EpiPen rival

Drugstore chain CVS Health Corp has cut the price of a generic version of Impax Laboratories Inc's emergency allergy injection, a device similar to Mylan NV's controversial EpiPen.

Jan 12 2017

BRIEF-U.S. FDA accepts BLA for Mylan and Biocon's proposed biosimilar trastuzumab

* U.S. FDA accepts biologics license application (BLA) for Mylan and Biocon's proposed biosimilar trastuzumab

Jan 11 2017

BRIEF-Biocon Ltd says USFDA accepts BLA for Mylan & co's proposed biosimilar trastuzumab

* Says U.S. FDA accepts Biologics License Application (BLA) for Mylan and Biocon's proposed biosimilar trastuzumab

Jan 11 2017

BRIEF-Prophase labs announces agreement to sell cold-eeze(r) brand

* Prophase labs announces agreement to sell cold-eeze(r) brand

Jan 09 2017

Pharma's middlemen will feel the squeeze in 2017

NEW YORK (Reuters Breakingviews) - The pharmaceutical industry's middlemen face a 2017 clampdown. The U.S. medical system's opacity and complexity have stoked drug prices, fueling the flow of dollars to insurers, wholesalers and pharmacy benefit managers (PBMs). The growth of high-deductible insurance - primed to accelerate under the incoming Trump administration - will bring much-needed transparency to the market, and unaccustomed pressure on these firms.

Dec 30 2016

Mylan launches EpiPen generic at $300 per two-pack

Mylan NV, which has come under fire for its drug pricing, said on Friday it would start selling a generic version of its life-saving EpiPen allergy treatment for $300 per two-pack, a more than 50 percent discount. | Video

Dec 16 2016

U.S. states sue Mylan, Teva, others for fixing drug prices

WASHINGTON Two years after high generic drug prices became a public controversy, legal cases are starting to land.

Dec 15 2016

EpiPen maker Mylan to restructure, cut workforce

Generic drugmaker Mylan NV , which has been under fire for price hikes on the life-saving EpiPen allergy treatment, said on Wednesday that it expected to cut less than 10 percent of its workforce in a restructuring to integrate acquisitions.

Dec 07 2016

BRIEF-Mylan NV enters into a revolving credit agreement

* Mylan NV says on November 22, 2016, entered into a revolving credit agreement

Nov 29 2016

Earnings vs. Estimates